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ABSTRACT Cryptococcus gattii is a pathogenic yeast of humans and other animals
which causes disease predominantly in immunocompetent hosts. Infection begins
when aerosolized yeast or spores enter the body, triggering an immune response,
including engulfment by macrophages. To understand the early transcriptional sig-
nals in both the yeast and its mammalian host, we performed a time-course dual-
transcriptome sequencing (RNA-seq) experiment for four lineages of C. gattii (lin-
eages VGI to IV) interacting with mouse macrophages at 1, 3, and 6 h postinfection.
Comparisons of in vitro to ex vivo gene expression levels indicated that lineage VGII
is transcriptionally divergent from non-VGII lineages, including differential expression
of genes involved in capsule synthesis, capsule attachment, and ergosterol produc-
tion. Several paralogous genes demonstrated subfunctionalization between lineages,
including upregulation of capsule biosynthesis-related gene CAP2 and downregula-
tion of CAP1 in VGIII. Isolates also compensate for lineage-speciﬁc gene losses by
overexpression of genetically similar paralogs, including overexpression of capsule
gene CAS3 in VGIV, which have lost the CAS31 gene. Differential expression of one
in ﬁve C. gattii genes was detected following coincubation with mouse macro-
phages; all isolates showed high induction of oxidative-reduction functions and
downregulation of capsule attachment genes. We also found that VGII switches ex-
pression of two laccase paralogs (from LAC1 to LAC2) during coincubation of macro-
phages. Finally, we found that mouse macrophages respond to all four lineages of
C. gattii by upregulating FosB/Jun/Egr1 regulatory proteins at early time points. This
report highlights the evolutionary breadth of expression proﬁles among the lineages
of C. gattii and the diversity of transcriptional responses at this host-pathogen inter-
face.
IMPORTANCE The transcriptional proﬁles of related pathogens and their responses
to host-induced stresses underpin their pathogenicity. Expression differences be-
tween related pathogens during host interaction can indicate when and how these
genes contribute to virulence, ultimately informing new and improved treatment
strategies for those diseases. In this paper, we compare the transcriptional proﬁles of
ﬁve isolates representing four lineages of C. gattii in rich media. Our analyses identi-
ﬁed key processes, including those involving cell capsule, ergosterol production, and
melanin, that are differentially expressed between lineages, and we found that VGII
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has the most distinct proﬁle in terms of numbers of differentially expressed genes.
All lineages have also undergone subfunctionalization for several paralogs, including
capsule biosynthesis and attachment genes. Most genes appeared downregulated
during coincubation with macrophages, with the largest decrease observed for cap-
sule attachment genes, which appeared to be coordinated with a stress response, as
all lineages also upregulated oxidative stress response genes. Furthermore, VGII up-
regulated many genes that are linked to ergosterol biosynthesis and switched from
expression of the laccase LAC1 to expression of LAC2 ex vivo. Finally, we saw a pro-
nounced increase in the FosB/Jun/Egr1 regulatory proteins at early time points in
bone marrow-derived macrophages, marking a role in the host response to C. gattii.
This work highlights the dynamic roles of key C. gattii virulence genes in response
to macrophages.
KEYWORDS Cryptococcus, capsule, ergosterol, host response, host-pathogen
interactions, laccase, mRNA
Infectious diseases impose a huge burden on human society. In recent years, fungihave gained widespread attention for their ability to threaten both animal and plant
species on a global scale (1, 2). However, many features of fungal genomes and
transcriptomes that enable the infection of diverse hosts and ecological niches remain
largely unexplored, especially for emerging pathogens (3, 4). One such example is the
basidiomycete yeast Cryptococcus gattii, which can cause pneumonia and meningoen-
cephalitis in humans (5). While C. gattii causes less overall global morbidity than its
sibling species C. neoformans, lineages have emerged with hypervirulent clinical phe-
notypes, a process that was most strikingly observed in the Paciﬁc Northwest of the
United States in the late 1990s (6). C. gattii is comprised of four genetically distinct
lineages designated the VGI to VGIV molecular types, among which lineage VGII has
been found to be associated with the highly virulent subtypes seen in the United
States. These lineages are sufﬁciently divergent to include 737 lineage-speciﬁc gains
and/or losses of genes across all four lineages (approximately 4% of the genes in any
given isolate), including DNA transposons and genes involved in the response to
oxidative stress and import into mitochondrial inner membrane (7).
In addition to genetic differences between lineages, changes in gene regulation
underlie important morphological and physiological traits in fungal pathogens (8, 9).
However, the mechanisms of gene regulation, evolution of gene networks, and rewir-
ing of transcriptional modules within lineages remain largely uncharacterized for many
infectious diseases, including those caused by C. gattii. New virulent lineages can
emerge through mutation and/or recombination events (10), which in turn lead to
different transcriptional proﬁles and enhanced virulence proﬁles, such as that of the
hypervirulent C. gattii VGIIa sublineage in the Paciﬁc Northwest (11), which descends
from two alpha mating-type parents (6) and is characterized by enhanced intracellular
parasitism (11).
Previous studies have demonstrated unique expression proﬁles among different
isolates of Cryptococcus under various conditions. For example, in C. neoformans
reference isolate H99, genes encoding membrane transporters for nutrients, general
metabolism, and oxidative stress response have been shown to be upregulated in the
presence of macrophages (12) and amoebae (13). Janbon et al. also characterized
differential expression of transporters, transcription factors, and genes involved in lipid
metabolism in C. neoformans in comparisons between rich media, limited/starved
media, and pigeon guano (14). In addition to analyzing protein-coding gene expres-
sion, Janbon et al. also identiﬁed nearly 1,200 miscellaneous RNAs that may perform a
range of functions that include morphogenesis via small open reading frames (ORFs) or
noncoding RNA (ncRNA) with structural or regulatory roles. Concurrently, Chen et al.
described an increase in genes involved in metabolic processes, alkaline response, salt
tolerance, and oxidative stress for two C. neoformans isolates grown in cerebral spinal
ﬂuid compared to growth in rich media (15).
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Few studies have focused on gene expression in C. gattii, although, notably,
Ngamskulrungroj et al. identiﬁed an upregulation of laccase genes involved in melanin
formation, and of other genes involved in cell wall assembly and metabolism in C. gattii
VGIIa outbreak strain R265, relative to the nonoutbreak C. gattii VGIIb strain in minimal
medium (16). In this report, we extend the description of C. gattii gene expression levels
to characterize variation across all four major lineages of C. gattii, including the
outbreak strain VGIIa R265 and a nonoutbreak isolate, ENV152, also from the VGIIa
subgroup, both in vitro and at three early time points (1, 3, and 6 h) following
coincubation and engulfment by murine bone marrow-derived macrophages (BMDMs).
Furthermore, we describe concurrent expression changes in mouse macrophages
during C. gattii coincubation, demonstrating the potential for the simultaneous proﬁl-
ing of both host and pathogen responses.
RESULTS
To identify mammalian and Cryptococcus gattii genes that are activated during
infection, we performed transcriptome sequencing (RNA-seq) across ﬁve C. gattii
isolates representing four lineages (VGI, VGII, VGIII, and VGIV), including an environ-
mental and clinical isolate from VGII, both in vitro and at time points 1, 3, and 6 h
postcoincubation with BMDMs (ex vivo). Each of the sequencing runs (n  40) yielded
between 904,770 and 17.6 million 30mer reads (10.9 gigabases of total sequence) (see
Table S1, tab 1, and Fig. S1, S2, and S3 in the supplemental material), except for VGIV
at h 6 (t6), which failed to yield sequencing data. Most of the sequences derived from
mouse (84% to 99% for each data set), while C. gattii reads ranged from up to 56.97%
(in vitro without macrophages; see Materials and Methods for mapping description) to
between 0.02% and 1.44% reads ex vivo (mean of 38,949 reads) (Fig. S2). The C. gattii
data sets formed two main clusters: (i) t0 (in vitro) for all isolates, probably owing to the
large difference in read counts between samples, and (ii) VGII isolates at any time point
(Fig. 1a). In contrast, gene expression in mouse macrophages clustered by time point
(Fig. 1b).
Differential expression was computed using the quantile-adjusted conditional max-
imum likelihood (qCML) method implemented in EdgeR (17), requiring a false-
discovery-rate (FDR) P value of 1e3 and at least 4-fold change in trimmed mean of
M-values (TMM) normalized fragments per kilobase of transcript per million mapped
reads (FPKM) to be considered a signiﬁcantly differentially expressed gene (DEG). To
check for the effect of different read depths on DEG prediction, subsets were created
and reanalyzed. This analysis identiﬁed consistent numbers of DEGs in vitro and more
variable numbers between infection time points (Fig. S4).
VGII is transcriptionally divergent in vitro from other C. gattii lineages. Pairwise
expression values for all C. gattii isolates in vitro (t0) revealed 524 DEGs between one or
more isolates, indicating that nearly 1 in 10 (8.1%) of all C. gattii protein-coding genes
situated throughout the genome (n  6,456) are uniquely differentially regulated
among the four divergent lineages, despite being all cultured in the same rich media
at 37°C with 5% CO2 (Fig. 2a and e) (see also Data Set S1 in the supplemental material).
A G-test of goodness of ﬁt based on the numbers of in vitro DEGs per lineage (not
considering speciﬁc genes) suggested differences (G 328.52, X-squared df  4, P
value  2.2e16), and pairwise comparisons using G-tests with Bonferroni multiple
correction also showed differences in VGII isolates compared with VGI, VGII ENV152,
and VGIV isolates but not VGII R265 (P value 2.2e16). Results of comparisons of VGIV
to VGI or VGIII were also highly distinct for numbers of DEGs (P value  2.2e16).
Of the 524 in vitro DEGs, 203 were differentially regulated in both VGII isolates, 245
additional genes were differentially regulated only for an individual VGII isolate, and 50
were differentially regulated inconsistently across VGII (e.g., upregulated in VGIV versus
VGII R265 and upregulated in VGI versus both VGII isolates). While some of these genes
were also differentially expressed in other lineages, only 5% (n  27) of in vitro DEGs
were unique to VGI, VGIII, or VGIV isolates, suggesting that VGII harbors expression
proﬁles distinct from those seen with the other lineages. Furthermore, the greater
Transcriptional Heterogeneity of Cryptococcus gattii
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FIG 2 The number of Cryptococcus gattii genes up- and downregulated between lineages in vitro (a) and between time points (b)
and principal-component analysis (PCA) of differentially expressed genes in vitro (c) and between time points (d) and the locations
of those genes in their genomes (synteny plotted using Synima [48]) alongside a phylogenetic tree constructed with RAxML (GTRCAT)
with 1,000-bootstrap support (shown as asterisks) (e). Genes are considered differentially expressed where the FDR P value is 0.001
and the TMM FPKM is greater than 4-fold. Colored boxes show the genomic locations of differentially expressed genes (DEGs) with
colors corresponding to panels a and b: in vitro, yellow; t0 versus another time point, blue; t1 versus another time point, red; t3 versus
another time point, green; t6 versus another time point, purple.
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number of genes uniquely differentially expressed within isolates of the VGII isolates
suggests that substantial differences exist even within the VGIIa sublineage. Further-
more, VGII and VGIII isolates were distinct from each other by principal-component
analysis (PCA) (Fig. 2c), while VGI and VGIV were not distinct from each other.
To understand the role that differential expression may play in each isolate in vitro,
we opted to use both a targeted approach (looking at known genes of interest [18],
including 35 capsule biosynthesis genes, 40 capsule attachment genes and cell-wall
remodeling genes, and 20 ergosterol genes based on their orthology to C. neoformans
H99 [7]) and a nontargeted approach (gene ontology term [GO-term] and PFAM
enrichment). Of the 524 unique DEGs, 8/35 were involved in capsule biosynthesis, 10/40
in capsule attachment and cell-wall remodeling, and 4/20 in ergosterol production, and
both laccase genes were differentially expressed in at least one pairwise comparison
(Fig. 3). These gene categories are therefore enriched for DEGs based on the results of
a hypergeometric test (P[X x]  P  1.207e07).
In vitro C. gattii lineages have distinct expression for capsule biosynthesis and
attachment genes. Capsule biosynthesis genes were differentially expressed between
lineages in vitro (Fig. 3), including CAS3, which was upregulated in VGIV compared with
all the other isolates. CAS3 mutants have a reduced capsule under conditions of
combination with cas31Δ, cas32Δ, or cas33Δ mutants and have a partial defect in
O-acetylation, leading to reduced overall levels of this modiﬁcation (18, 19). Meanwhile,
the closely related paralog CAS31 is absent in VGIV and VGIIIb (but present in the VGI,
VGII, and VGIIIa lineages) (Fig. S5) and as such has no detectable expression (zero TMM
FPKM for both “replicates”)—manifesting as downregulated compared with each of the
other lineages. Similarly, CAP1 is upregulated in VGII and VGIV isolates relative to VGI
and VGIII isolates, while the close paralog CAP2 is upregulated in VGIII compared with
VGII. Other differentially expressed capsule biosynthesis genes may not be fully com-
pensated by genetically similar paralogs, such as the hexose transporter HXT1 down-
regulated by both VGII isolates.
Capsule attachment and cell-wall remodeling genes were also differentially ex-
pressed between lineages of C. gattii (Fig. 3). For example, chitin synthases CHI4 and
CHS2 were upregulated in both VGII isolates. Chitinase CHI2 was upregulated in VGIV.
Chitin deacetylase 1 (CDA1) was highly expressed by all isolates in vitro (TMM FPKM
ranging from 932 to 2,265 across all replicates) and was not identiﬁed as differentially
expressed. However, CDA2 was upregulated in VGI and VGII isolates compared with
VGIII and VGIV. Meanwhile, CDA3was upregulated in VGIV compared with VGII and VGIII
(perhaps again showing a change in paralog expression regulation). Both CDA2 and
CDA3 mutants have increased capsule size when combined with cda1Δ mutants (18),
however, CDA1 was not found to be differentially expressed.
Differential expression of known drug targets and virulence genes. In common
with most fungi, ergosterol is found in the membrane of C. gattii and is a key target for
numerous antifungal drugs including ﬂuconazole and amphotericin B (20). The VGII
lineage had signiﬁcantly higher expression for several genes involved in ergosterol
production, including NADPH-ferrihemoprotein reductase genes, ERG1 (squalene
monooxygenase), ERG25 (methylsterol monooxygenase), and SRE1. Each of these genes
are linked to drug resistance or the oxidative stress response; for example, ERG1
mutants have increased ﬂuconazole susceptibility in Candida glabrata (21), ERG25 has
a moderate susceptibility to hypoxia and the endoplasmic reticulum (ER) stress-
inducing agent dithiothreitol (DTT) in Aspergillus fumigatus (22, 23), and SRE1 is required
for hypoxic induction of genes coding for oxygen-dependent enzymes involved in
ergosterol synthesis in C. neoformans (24).
Laccases are cell wall enzymes that catalyze melanin to protect Cryptococcus from
various stresses, including oxidative stress, and are therefore considered important
virulence factors (25). Laccase production in both C. gattii and C. neoformans is
controlled by two cell wall enzymes that control melanin production (25). VGIV signif-
icantly upregulates both copies (LAC1 and LAC2) in vitro compared with VGIII and all the
Farrer et al.
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other isolates, respectively. Whereas LAC1 and LAC2 ﬂank each other in C. neoformans,
C. gattii has an additional gene (CNBG_2145) encoding a hypothetical protein with no
functional annotation (PFAM, GO, KEGG) in the middle. This gene, unlike LAC1 and
LAC2, was not consistently expressed by any of the lineages under any conditions.
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Differential expression levels among isolates in vitro were also enriched (two-tailed
Fisher’s exact test with false-discovery-rate [FDR {q-value}] analysis) for several GO-
terms compared with the remaining genes (Table 1). Enriched terms included “oxida-
tive reduction” (q 1.85E07) and oxidoreductase activity (q 0.011). Genes with the
oxidative reduction GO-term, including those coding for ferric reductases, metallore-
ductases, nitric oxide dioxygenases, acidic laccases, oxidoreductases, and various de-
hydrogenases, were both up- and downregulated by each isolate. VGII isolates had the
greatest number of upregulated genes assigned an oxidative reduction function: VGII
ENV152 (n  39), VGII R265 (n  23), compared with VGIII (n  18), VGIV (n  11), and
VGI (n  7). All R265 genes, apart from the single gene CNBG_2804 (encoding a
hypothetical protein with a DUF455 domain), were also found in ENV152. The remain-
ing 17 uniquely upregulated genes in ENV152 included genes encoding ﬁve dehydro-
genases (methylmalonate-semialdehyde, 3-hydroxyacyl-coenzyme A [hydroxyacyl-
TABLE 1 Enrichment of functional annotation for in vitro and ex vivo comparisonsa
GO/PFAM designation Isolate Count 1 Count 2 Fisher P q value Rel. prop GO description
Sig. enriched terms from
in vitro comparisons
GO:0055114 64 256 1.13E10 1.85E07 2.54 Oxidation reduction
GO:0016638 5 2 1.01E04 1.11E02 25.41 Oxidoreductase activity, acting on the
CH-NH2 group of donors
GO:0050660 13 32 9.79E05 1.11E02 4.13 FAD binding
PF00083.19 18 54 2.26E05 2.66E02 3.56 Sugar (and other) transporter
GO:0004553 12 33 4.15E04 3.25E02 3.7 Hydrolase activity, hydrolyzing
O-glycosyl compounds
GO:0005975 25 116 7.41E04 4.86E02 2.19 Carbohydrate metabolic process
Sig. depleted terms from
in vitro comparisons
GO:0043234 3 211 3.35E06 6.14E04 0.14 Protein complex
GO:0034645 11 316 6.33E05 9.42E03 0.35 Cellular macromolecule biosynthetic
process
GO:0006396 2 142 2.60E04 2.25E02 0.14 RNA processing
GO:0003723 2 137 3.78E04 3.11E02 0.15 RNA binding
GO:0005737 35 597 7.23E04 4.86E02 0.6 Cytoplasm
GO:0015031 2 126 7.96E04 4.86E02 0.16 Protein transport
Sig. enriched terms from
ex vivo comparisons
GO:0055114 VGI WM276 18 302 3.56E05 4.63 Oxidation reduction
GO:0016491 VGI WM276 18 376 4.52E04 3.72 Oxidoreductase activity
GO:0006364 VGII ENV152 34 13 1.93E12 10.64 rRNA processing
GO:0005730 VGII ENV152 25 6 7.74E11 16.95 Nucleolus
GO:0003735 VGII ENV152 54 58 7.37E10 3.79 Structural constituent of ribosome
GO:0006412 VGII ENV152 71 117 4.27E07 2.47 Translation
GO:0003723 VGII ENV152 51 88 1.32E04 2.36 RNA binding
GO:0005506 VGII ENV152 35 51 3.66E04 2.79 Iron ion binding
GO:0055114 VGII ENV152 95 225 5.04E04 1.72 Oxidation reduction
GO:0016627 VGII ENV152 13 8 1.32E03 6.61 Oxidoreductase activity, on CH-CH
GO:0008026 VGII ENV152 24 32 2.60E03 3.05 ATP-dependent helicase activity
GO:0016627 VGII R265 11 10 4.25E04 9.6 Oxidoreductase activity, on CH-CH
GO:0022900 VGII R265 8 7 8.59E03 9.97 Electron transport chain
GO:0020037 VGII R265 11 17 8.59E03 5.64 Heme binding
GO:0016491 VGIII CA1873 33 361 9.41E04 2.57 Oxidoreductase activity
GO:0055114 VGIII CA1874 28 292 1.77E03 2.69 Oxidation reduction
Sig. depleted terms from
ex vivo comparisons
GO:0043234 VGII ENV152 20 194 1.39E03 0.42 Protein complex
GO:0006508 VGII ENV152 12 132 9.48E03 0.37 Proteolysis
aEnrichment of functional annotation for in vitro and ex vivo comparisons was determined by a two-tailed Fisher exact test with a q-value (Storey-Tibshirani) FDR,
where count 1 data represent numbers of terms and parent terms in the differentially expressed set and count 2 data represent the remaining terms and parent
terms in the non-differentially expressed set. The uncorrected Fisher P values, corrected q values, relative-proportion (Rel. Prop) values, and descriptions are provided
for each term (requiring q values of 0.05 for each). FAD, ﬂavin adenine dinucleotide; Sig., signiﬁcantly.
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CoA], glutaryl-CoA, glyceraldehyde-3-phosphate, and glutamate), the Fe-Mn family
superoxide dismutase, and ferric reductase transmembrane component 4. Only a single
PFAM, a PF00083.19 sugar (and other molecule) transporter, was found to be enriched
in the in vitro comparisons. The ability of C. gattii to respond to host- and environment-
derived oxidative stress is well described (22, 26, 27), and it is noteworthy that
differences in expression levels between isolates and lineages were found even under
in vitro conditions.
One in ﬁve C. gattii genes is differentially expressed under in vitro and ex vivo
conditions among the lineages. Pairwise comparisons of expression values for each
lineage at different time points (t0 versus t1, t3, and t6) identiﬁed 1,193 unique DEGs,
the majority of which were upregulated in vitro versus ex vivo (Fig. 2b) (see also Data
Set S1, tab 2). About 1/3 (60%) (n  309) of these genes were also differentially
expressed in an interlineage in vitro comparison, leaving 215 genes that were uniquely
differentially expressed in vitro. PCA showed large differences between t0 and ex vivo
time points in both VGII isolates (Fig. 2d).
Genes of interest (capsule, ergosterol, and laccases) were enriched for DEGs at
different time points based on the results of a hypergeometric test (P[X x]) 
P  0.007), including nine capsule biosynthesis genes (all VGII), 11 capsule attachment
and cell-wall remodeling genes (all downregulated ex vivo), 14 ergosterol genes, and
both laccase genes (Fig. 4). Separately, many (n 40/97; 41%) C. neoformans genes that
were previously found to be differentially expressed via microarray in the presence of
amoebae and macrophages (13) were similarly modulated in C. gattii (111 genes with
similar or different modulation results between amoebae and macrophages, 97 of
which had a C. gattii ortholog, 56 of which were also C. gattii DEGs between time points,
and 40 of which had the same directionality) (Data Set S1, tab 3).
Genes differentially expressed ex vivo were statistically signiﬁcantly enriched (two-
tailed Fisher’s exact test with q-value FDR) for 18 GO-terms and no PFAM terms
(Table 1). Strikingly, the oxidoreductase activity term was enriched in each lineage and
isolate (apart from VGIV, which had only 20 differentially expressed genes and thus no
enriched terms). The ability of C. gattii to respond to host- and environment-derived
oxidative stress is thus a signiﬁcant feature of genes that are differentially expressed
(both between lineages in vitro and under in vitro versus ex vivo conditions). Additional
terms included iron ion binding and terms related to ribosomes (i.e., processing of
rRNA, a structural constituent of ribosome) for VGII ENV152, perhaps indicating an
increase in translational activity.
Capsule biosynthesis genes in VGII were differentially expressed in the presence of
macrophages (Fig. 4). For example, CAP1 and UGT1 were downregulated by both VGII
isolates, while CAP4, CAS3, and UGD1 were all upregulated at one or more of the ex vivo
time points. Other capsule biosynthesis DEGs included CAS35 (the CAS35Δ mutant has
a decreased capsule [19]), which was upregulated in R265 at t3 versus t0; UXS1 (the
uxs1Δ capsule is missing xylose [28]), which was upregulated in R265 at t1 and t3 versus
t0; and CAS1 (the cas1Δ mutant has a defect in capsule O-acetylation and reactivity to
GXM antibodies [29]), which was upregulated in VGII ENV152 at t3.
Capsule attachment and cell-wall remodeling genes were also differentially ex-
pressed ex vivo, predominantly by VGII isolates, and were all downregulated ex vivo
(Fig. 4). For example, chitin synthase genes CHS4 and CHS8 were upregulated in vitro in
VGII compared with any other time points ex vivo. Chitins generated by such chitin
synthases are converted into chitosan by the chitin deacetylase genes CDA1, CDA2, and
CDA3, where it constitutes an important component of the cell wall of Cryptococcus
(30). Both CDA1 and CDA2 are downregulated ex vivo in one or more of the lineages of
C. gattii, apart from VGIV.
The four ergosterol genes (CNBG0583/CNAG01003, ERF1, SRE1, and ERG25) that were
upregulated in VGII compared with VGIII and VGIV in vitro were also upregulated in VGII
in vitro compared with the three ex vivo time points, again suggesting that these are
downregulated during infection. However, nine additional ergosterol biosynthesis
genes, including ERG2, ERG6, ERG7, ERG13, ERG20, and ERG26, were each upregulated in
Transcriptional Heterogeneity of Cryptococcus gattii
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the VGII isolates at 3 h postinfection compared with the levels seen in vitro, suggesting
that these genes are activated between 1 and 6 h after coincubation with macro-
phages.
The laccase genes that produce melanin and that are upregulated in VGIV in vitro
compared with the other lineages are also differentially expressed in VGII between in
vitro and ex vivo conditions. Speciﬁcally, LAC1 (CNBG2144) in VGI and VGII is down-
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regulated ex vivo. In contrast, LAC2 (CNB2146) is upregulated in both VGII isolates at t3
compared with t0—demonstrating that during infection, VGII isolates switch expres-
sion from LAC1 to LAC2.
Mouse macrophage response to C. gattii. Mouse BMDM expression for each of
58,716 annotated mouse transcripts (including protein-coding genes and pseudogenes
and other non-protein-coding genes) was highly consistent under in vitro conditions
and conditions of coincubation with any of the four lineages of C. gattii at any of the
three time points (Fig. 5), perhaps indicating low rates of yeast engulfment or the
general low immunogenicity of cryptococci. In this case, differential expression of C.
gattii ex vivo (see previous section) may be caused by indirect effects of macrophage
coincubation. Only 24 upregulated DEGs and 42 downregulated DEGs were identiﬁed
in total (Data Set S1, tab 4). Of those 24 upregulated genes, ﬁve separate/unique FBJ
osteosarcoma viral oncogenes (speciﬁcally, FOSB and the truncated splice form Δfosb2)
belonging to the eight most highly differentially expressed genes (log fold change 
3.58 to 7.78) were found at t1 for VGII R265 only. FOS genes encode a leucine zipper
protein that dimerizes with the Jun family (among which JunB is also upregulated at t3
in VGII ENV152), forming the AP-1 transcription factor, which in turn regulates diverse
functions, including cell proliferation, differentiation, and transformation, following the
primary growth factor response. Perhaps it is therefore unsurprising that 20% of
upregulated genes (n  11/52 redundant upregulated genes), including EGR1-201 and
EGR1-202, at t3 for all ﬁve C. gattii isolates tested and EGR3 at t1 for VGII R265 only,
belonged to the early growth response protein 1 family genes.
Most of the genes downregulated in mouse macrophages during infection appear
to be signaling molecules and transcription factors, including ETV5 (ETS transcription
factor variant 5), which is downregulated at t6 in all C. gattii isolates except VGIV. Other
downregulated genes include those encoding the DENND2C proteins at t3 in VGII
ENV152 and at t1 in VGII R265. DENND2C proteins act in diverse intracellular signaling
pathways via GDP/GTP exchange, with many potential downstream targets. Addition-
ally, DNA-binding protein ID1 (which inhibits basic helix-loop-helix [bHLH] transcription
factors) was downregulated at t6 in VGI, VGII ENV152, and VGIII, as well as t1 in VGII
R265. Similarly, dual speciﬁc protein phosphatase 6 (DUSP6), involved in mitogen-
activated protein kinase (MAPK) signaling, was downregulated at t6 in VGI, VGII ENV152,
and VGIII, while DUSP4 was also downregulated at t6 in VGI only.
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DISCUSSION
The transcriptional responses of host and pathogen during infection can reveal key
insights into their interactions and the molecular basis of pathogenicity. Transcriptional
differences between distantly related isolates in culture can also reveal the impact of
their genetic divergence and explain epidemiological differences. In this study, we
compared the expression proﬁles of ﬁve isolates belonging to the four lineages of C.
gattii in vitro between three early time points during coincubation with mouse bone
marrow-derived macrophages (BMDM) and, in parallel, characterized the host response.
Both C. gattii comparisons suggested that lineage VGII is transcriptionally divergent
from non-VGII lineages in terms of number of genes differentially expressed. For
example, only 5% of in vitro DEGs belonged to non-VGII isolates, despite these isolates
accounting for 30% of all pairwise comparisons made. It is likely that the loss of RNA
interference (RNAi) functionality in VGII (7, 31, 32) is partially responsible indirectly
(rewiring of gene regulatory responses in result to loss of Argonaut proteins) and
perhaps even directly (mRNA not being degraded).
VGII is responsible for nearly all C. gattii infections in the Paciﬁc Northwest (PNW)
(33), which is the location of the worst recorded outbreak of C. gattii infections
worldwide. In this study, we found that two subgroup VGIIa isolates had distinct
expression proﬁles, possibly owing to genetic variation generated from their different
sources of origin (environmental or clinical). VGII isolates also show a high degree
(albeit across a range) of virulence traits, including rate of intracellular proliferation
within macrophages (R265 1.8  0.1 and ENV152 2.3  0.2 compared with VGI
WM276 0.98  0.2 and VGIV CBS10101 1.23  0.3), average mitochondrial
tubularization percentage (R265 58.4% and ENV152 44.5% compared with VGI
WM276 14.3% and VGIV CBS10101  21.6%), average phagocytosis percentage
(R265 31.4% and ENV152 20.5% compared with VGI WM276 11.1% and VGIV
CBS10101  8.6%), and macrophage cell death percentage (R265 15.2% and
ENV152 12.3% compared with VGI WM276 16.8% and VGIV CBS10101  12%) (34,
35). VGIII isolate CA1873 was not evaluated for these phenotypic traits in those two
papers. Therefore, isolates within lineages demonstrate high phenotypic variability.
Although the sequenced isolates in this study are representative of each lineage,
comparing multiple isolates from each lineage would help delineate the intralineage
versus interlineage variations in gene expression.
The capsule biosynthesis pathway in C. gattii constitutes a complex trait controlled
by numerous genes. Many of these genes presented various degrees of expression
among the four lineages in vitro, suggesting the presence of diverse mechanisms
operating to maintain and perhaps even diversify the properties of the capsule.
However, non-VGII lineages did not differentially express capsule synthesis genes ex
vivo, suggesting that they are perhaps less rigorously regulated (expressed under more
diverse conditions) or expressed less abundantly or are perhaps less sensitive to
host-derived stresses and stimuli. One such gene, CAS3, is upregulated by VGII isolates
at multiple time points ex vivo compared with in vitro. CAS3 has previously been
identiﬁed as upregulated in VGII R265 compared with low-virulence VGII isolate R272
under conditions of carbon and nitrogen starvation (16). However, we found no
evidence of differential expression of CAS3 between VGII R265 and VGII ENV152—
possibly indicating a uniqueness of R272 expression or experimental differences be-
tween studies. However, we found that CAS3 is upregulated by VGIV CBS10101 in vitro
compared with other isolates, while close paralog CAS31 is a lineage-speciﬁc gene
missing in VGIV (7). It is therefore possible that VGIV is overexpressing CAS3 to
compensate for its CAS31 deletion or disruption and demonstrating subfunctionaliza-
tion of these paralogs. Furthermore, cas31Δ mutants have previously been shown to
manifest minor differences in GXM composition in C. neoformans (18, 19), which may
also manifest in C. gattii VGIV as well as in VGIIIb. Separately, the capsule biosynthesis
gene CAP2 is upregulated by VGIII, while CAP1 is downregulated by VGI and VGIII,
suggesting a lineage transition from expressing one gene to expressing another.
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Capsule attachment DEGs (in comparison to capsule biosynthesis genes) were all
downregulated ex vivo, suggesting that these do not play an active role during
infection.
Ergosterol in the membrane of C. gattii is a key target for numerous antifungal
drugs, including ﬂuconazole and amphotericin B (20). VGII presented higher expression
for genes involved in ergosterol production in vitro, including upregulation of ERG1,
ERG25, SRE1, and an NADPH-ferrihemoprotein reductase gene. Mutants for each of
these genes show a range of defects in the presence of antifungals or hypoxia (21–24).
ERG1, ERG25, and SRE1 were also upregulated in VGII in vitro compared with the three
ex vivo time points, suggesting that these genes can be switched off during non-drug-
related stresses. However, a further nine ergosterol genes were upregulated between
1 and 6 h postinfection, including ERG2, ERG6, ERG7, ERG13, ERG20, and ERG26,
suggesting that this pathway is active during infection. The biological signiﬁcance of
these expression differences are unclear but could manifest in lineage-speciﬁc drug
resistance variations.
Laccase production in both C. gattii and C. neoformans is controlled by two cell
wall enzymes (encoded by LAC1 and LAC2) that possess a broad spectrum of
activity, oxidizing both polyphenolic compounds and iron (25). VGIV upregulates
both genes compared with other lineages in vitro. LAC1 is downregulated in VGI and
VGII ex vivo compared with in vitro, and LAC2 is instead upregulated in both VGII
isolates at t3 compared with t0—suggesting that C. gattii VGII switches expression from
one laccase gene to the other during infection, perhaps due to changing concentra-
tions or requirements for metabolism of lactose and galactose or for production of
melanin. In C. neoformans, LAC1 and LAC2 (along with capsule genes) are part of the
Gpa1-cAMP pathway, which regulates capsule and melanin production using L-3,4-
dihydroxyphenylalanine (L-dopa) as a substrate (36). We hypothesize that VGII uses
LAC2 to regulate growth and glucose responses (and potentially virulence) instead of
LAC1. In C. neoformans, LAC1 is localized to the cell wall, whereas LAC2 is cytoplasmic
but is capable of localizing to the cell wall (37); therefore, C. gattii LAC2 could behave
similarly to its C. neoformans counterpart, which may have increased versatility during
infection of macrophages.
We also identiﬁed differential expression levels in VGII lineage-speciﬁc genes such as
those encoding an MFS transporter and an oxidoreductase that may have contributed
to the enrichment of oxidative reduction, which was identiﬁed in both in vitro com-
parisons and in vitro versus ex vivo comparisons. This term includes a wide range of
functions, pathways, and genes, including those encoding ferric reductases, metallore-
ductases, nitric oxide dioxygenases, acidic laccases, oxidoreductases, and various de-
hydrogenases. Previously, an upregulation of genes involved in oxidative stress has
been identiﬁed in C. neoformans isolate H99 coincubated with the J774A macrophage-
like cell line for 16 h versus in vitro conditions (12) and in C. gattii VGII isolate R265
versus isolate R272 under carbon and nitrogen starvation conditions (16). The ability of
C. gattii to respond to host- and environment-derived oxidative stress is well de-
scribed—and it is consistent that genes involved in these processes should also be
enriched between isolates and lineages at the expression level in vitro and among
lineages at different time points ex vivo.
Finally, we found that mouse macrophages respond to C. gattii by upregulating
FosB/Jun/Egr1 regulatory proteins at early time points, which may trigger differen-
tiation and cell division of macrophages. We found little evidence for differential
expression induced by different C. gattii lineages, suggesting that the macrophage
responses to C. gattii are the same across lineages. Our report highlights the
breadth of expression proﬁles among the lineages of C. gattii and the diversity of
transcriptional responses at this host-pathogen interface, some of which may be the
cause of the differences in phenotypic and clinical manifestations noted between
lineages (38).
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MATERIALS AND METHODS
Macrophage and Cryptococcus gattii infection assay. C. gattii was grown in accordance with
methods described in previous work (26). Brieﬂy, ﬁve strains of C. gattii were grown in RPMI/C10 media
with heat-inactivated (HI) fetal bovine serum (FBS) media and were preincubated at 37°C in C10 media
for 1.5 h before infection. Bone marrow-derived macrophages (BMDM) were derived from bone marrow
cells collected from the femur and tibia of C57BL/6 female mice. All mouse work was performed in
accordance with the Institutional Animal Care and Use Committees (IACUC) guidelines and with relevant
guidelines at the Broad Institute and Massachusetts Institute of Technology, with protocol 0615-058-1.
Primary bone marrow cells were grown in C10 media as previously described (39) and supplemented
with macrophage colony-stimulating factor (M-CSF) (Thermo Fisher Scientiﬁc) at ﬁnal concentration of
10 ng/ml to promote differentiation into macrophages.
For the infection experiment, dilutions of 7.5E5 cells were made for BMDM and C. gattii strains.
BMDM were spun at 500 relative centrifugal force (rcf) at 37°C for 2 min to adhere to plates, and
inoculated with C. gattii strains using a multiplicity of infection (MOI) of 1 macrophage to 2 C. gattii.
Macrophages with C. gattii cells were centrifuged at 500rcf at 37°C for 2 min. Next, cells were incubated
at 37°C with 5% CO2 for 1 h, 3 h, and 6 h postcentrifugation. In addition, we grew C. gattii in vitro, and
BMDM without C. gattii, in duplicate with the same C10 media. At the end of the time points, the medium
was removed, lysis buffer was added, and samples were placed in a 80°C freezer for RNA extraction.
RNA was extracted from population samples using a Qiagen RNeasy minikit. All samples were
subjected to 3 min of bead beating with 0.5-mm-diameter zirconia glass beads (BioSpec Products) in a
bead mill. Libraries were generated usinga TruSeq Stranded mRNA Library Prep kit (Illumina).
RNA-seq and data analysis. All samples were sequenced on an Illumina HiSeq 2500 system to
generate strand-speciﬁc paired-end reads that were 38 nucleotides (nt) in length. Raw reads from each
sample were sequenced on multiple lanes and so were merged into individual replicates. Using BLAST
searches of the nr database, we identiﬁed the following contaminants in each of the samples: Escherichia
coli K-12 MG1655, suicide vector pCD-RAsl1, and cloning vector pMJ016c (see Table S1, tab 1, in the
supplemental material). These contaminants were excluded from all of the read sets on the basis of
Bowtie2 (40) alignments. We next aligned all reads to mouse GRCm38 p4 mm10 transcript sets (including
protein-coding genes and pseudogenes and other categories of non-protein-coding genes) and ge-
nomes (41) using Bowtie2 (40). We took all reads that aligned to neither the mouse genome nor the gene
sets and aligned those reads to the R265 updated gene set (7) as well as the R265 genome using Bowtie2
(Table S1, tab 2). Bowtie2 alignments to mouse or C. gattii were run though the Trinity version
r20140413p1 (42) pipeline, using the following default parameters: max insert size 800, no-mixed (no
unpaired reads), no-discordant (does not satisfy the paired-end constraints), gbar 1,000 (disallow gaps
within 1,000 bases), and end-to-end (entire read must align from one end to other without any trimming
or soft clipping). To reveal the extent of the effect that this had on alignment data, we aligned R265 RNA
in vitro replicate A to the genome of R265 with Bowtie2 using nonstringent parameters. The overall
alignment rate increased from 56.97% to 68.62%. We also found that some reads that were left unaligned
by Bowtie2 were aligned by the separate tool BWA v0.7.4.
Other factors that were likely to reduce alignment coverage were the draft quality of the C. gattii
R265 genome and the gene sets used (see Fig. S1 in the supplemental material for evaluation of Core
Eukaroyotic Gene coverage)—as a consequence of the effects of those limiting factors, genuine C. gattii
mRNA would be unalignable. Another factor was that non-VGII isolates were aligned to VGII and that
certain differences, including lineage-speciﬁc gene differences, would reduce gene coverage. However,
the alignment strategy employed was deemed more suitable than aligning to individual lineage
reference sets and relying on orthologs, which would reduce the number of genes subjected to
comparisons and add errors caused by incorrect assignment of orthologs.
All reads from in vitro C. gattii experiments that were unaligned were assembled de novo using Trinity
(5,730 sequences of total length 2.1 Mb), genes predicted by Transdecoder (521 sequences of 270 kb),
and BLASTn searches of the NCBI nr database. Only 90 of these sequences (37 kb) did not align to either
the mouse genome or that of C. gattii R265. The remainder of the unaligned sequence that did not map
to mouse or C. gattii was highly repetitive and was enriched for Illumina adapter and control sequences.
Indeed, FASTQC v0.11.4 identiﬁed large fractions of the unaligned unprocessed reads derived from
Process Controls for TruSeq kits, which including 10% CTA and CTL as overrepresented sequences.
Reads that aligned only to coding sequence (CDS) from C. gattii or mm10 had their transcript
abundances estimated using RSEM (43) and differential expression levels (FDR P value  0.001 and
4-fold change of TMM-normalized FPKM) predicted using EdgeR (17) through the use of the Trinity
version r20140413p1 (46) pipeline. Speciﬁcally, the pipeline uses the EdgeR quantile-adjusted conditional
maximum likelihood (qCML) method after estimating common dispersion and tagwise dispersions using
the Cox-Reid proﬁle-adjusted likelihood method (also implemented in EdgeR). For Cryptococcus strains,
we estimated transcript abundance and differential expression in the same way after (i) merged time
points (i.e., calculations performed for each isolate only) and (ii) merged isolates (i.e., calculations
performed for each time point only). Merging of isolate data resulted in far weaker correlations between
replicates than merging of time point data, indicating that in vivo conditions were more inﬂuential on
overall expression values than lineage/strain-speciﬁc differences. Principal-component analysis (PCA) was
performed using SmartPCA from EIGENSOFT v4.0 (44), where each gene was given a value of 0 for
non-DEG and a value of 1 for DEG (upregulated).
Orthologs to genes of known function in C. neoformans H99 were identiﬁed in C. gattii R265 using
OrthoMCL (45) across 16 isolates as previously described (7). Genes of interest (capsule biosynthesis,
capsule attachment, and ergosterol genes) that fell within paralogous clusters had the sequences of 16
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isolates described previously (7) aligned using MUSCLE v3.8.31 (46), and a neighbor-joining tree was
constructed using PAUP version 4.0b10 (47) to decipher orthologs. Synteny was visualized using Synima
(48).
Of the 58,716 annotated mouse transcripts, 39,229 (67%) had evidence of expression in one or more
samples (TMM FPKM  1). Prior to differential expression analysis, we excluded 3,596 mouse transcripts
that any C. gattii in vitro RNA (i.e., no macrophage present) aligned to them. Surprisingly, some mouse
transcripts were very highly expressed in C. gattii-only samples (e.g., glutamate receptor interacting
protein 2 [Grip2-205] had a TMM FPKM value of 15,000 for every C. gattii isolate and values between
only 10 and 874 for t1, t3, and t6, which were time points when mouse macrophages were actually
present), perhaps owing to sequence similarity of some 30mers or to inaccuracies in the mouse gene set.
Applying the same threshold FDR P value of0.001 and4-fold change of TMM normalized FPKM using
EdgeR (17) identiﬁed 24 genes that were upregulated during infection by 1 or more isolates of C. gattii
and 42 genes that were downregulated during infection by 1 or more isolates of C. gattii.
Enrichment analyses for PFAM and GO terms previously assigned (7) were conducted using two-
tailed Fisher’s exact test with q-value FDR. Multiple testing corrections were performed with the
Storey-Tibshirani (49) method (requiring a q value of 0.05). For enrichment tests, we excluded PFAM
and GO terms related to transposable elements and domains of unknown function.
Impact of read depth on differential expression. On the basis of data quantity/transcriptome
coverage alone, the host response and in vitro C. gattii lineage expression differences should be the most
robust, while C. gattii ex vivo expression changes should be less robust. To explore the coverage and
sensitivity of our C. gattii RNA-seq data and pipeline, we ﬁrst made subsets (75%, 50%, and 25%) of our
C. gattii data and recalibrated the differential expression data (Fig. S3). The number of genes differentially
expressed between isolates under in vitro conditions remained most consistent in terms of number of
differentially expressed genes following subsetting (100%  1,208 genes, 75%  1,205, 50%  1,147,
25%  800) (Fig. S3A).
For all C. gattii data sets (those corresponding to in vitro conditions and individual isolates corre-
sponding to comparisons between conditions), the proportion of genes reidentiﬁed in the 75% subset
was between 79% to 100% (VGIV CBS10101 had the same 20 genes corresponding to both data set sizes)
(Fig. S3B). In contrast, the number of genes identiﬁed only in the full data sets increased in the remaining
subsets, with the most pronounced increase being that seen with VGIIa ENV152, which lost the
identiﬁcation of 476 genes in the 75% subset, possibly indicating a lack of data for this isolate (Fig. S3C).
We also assessed each subset for genes that were not found in the full set (i.e., genes that were unique
to the subsets; Fig. S3D). VGII and VGIV and the in vitro data sets had fewer unique genes as the subsets
became smaller, while VGI and VGIII had increases as the subsets became smaller.
Under in vitro conditions, between 10% to 15% of genes were unique in their subsets, while for VGII
ENV152, the proportion was between 1% and 5%. For isolates with very few identiﬁed differentially
expressed genes (such as VGIV CBS10101 and VGIII CA1873), the numbers of unique genes approached
or even exceeded the number found in the full data set. Given this variation, it is therefore likely that
most of the ex vivo C. gattii data sets would beneﬁt from deeper RNA-seq data and that the in vitro
expression values are more robust than the ex vivo data. Nevertheless, the majority of differential
expressed genes were consistent between the larger subsets of data.
Accession number(s). All RNA-seq data for mouse macrophages and C. gattii have been deposited
in the Short Read Achieve under accession no. PRJNA428946.
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